Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway-Reference-Cited by-同舟云学术

Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway

Published:2024-04-10 Issue:8 Volume:67 Page:6027-6043
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wang Zhijie¹²,Yuan Lin²,Liao Xiaotong²,Guo Xia¹,Chen Jianjun²^ORCID

Affiliation:

1. Shenzhen Key Laboratory of Viral Oncology, Ministry of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen 518100, China

2. Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China

Funder

Science and Technology Foundation of Shenzhen City

Southern Medical University

Science, Technology and Innovation Commission of Shenzhen Municipality

Organization Department of the Central Committee of the Communist Party of China

National Natural Science Foundation of China

Shenzhen Hospital, Southern Medical University

Shenzhen Key Laboratory of Viral Oncology

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c02143

Reference109 articles.

1. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

2. Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development

3. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

4. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes

5. Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor